Datos del Documento

Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/373
Título : Long-term antifracture efficacy and safety of antiosteoporotic treatments: the hidden part of the iceberg
Autor : Cannata Andía, Jorge B.
Palabras clave : Osteoporosis
Fragility fractures
Antiosteoporotic drugs
Sustained antifracturary efficacy
Fecha de publicación : 2009
Editorial : Artem
Citación : Medicographia.2009;32:18-24
Resumen : Long-term antifracture efficacy and safety are the two major goals of any antiosteoporotic treatments. So far, several drugs have proved to be effective and safe during the 2-3 years period of controlled clinical trials but only a few of them have shown bone protection up to 5 years, which is the minimum period in order to assume there is sustained fracture reduction. Raloxifene has shown efficacy in vertebral fracture risk reduction in up to 5 years but no effect in non-vertebral fracture. Risedronate and Alendronate have also shown anti-fracture efficacy in vertebral fracture risk reduction up to 7 and 10 years respectively, but no long-term benefit was observed in non-vertebral fracture. Strontium ranelate have demonstrated a sustained fracture risk reduction up to 5 years in vertebral and non-vertebral fractures. In addition, preliminary analyses of the 8 years treatment have shown the same trend in vertebral and non-vertebral fracture risk reduction. In summary, at least 4 drugs have demonstrated a sustained vertebral antifracture efficacy but only strontium ranelate has proved to be long-term efficient in non-vertebral fracture.
URI : https://ria.asturias.es/RIA/handle/123456789/373
ISSN : 0243-3397
Aparece en las colecciones: Open Access DRIVERset

Archivos en este documento:
Fichero Tamaño Formato  
Archivo.pdf315.58 kBAdobe PDFVer/Abrir
Mostrar el registro Completo

Ver estadísticas del documento

Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons